Open for forecastingClinical TrialsReleased Dec 16, 2025

GOOD-IDES-02 (imlifidase) Phase 3 anti-GBM

0 models evaluated0 runs0 votes
Run this in the Arena

Trial setup

- Trial: GOOD-IDES-02, global pivotal Phase 3 in anti-glomerular basement membrane (anti-GBM) disease. - Arms: imlifidase + standard of care vs standard of care. - Primary endpoint: renal function at 6 months, evaluated by eGFR (topline described as not met). - Key topline supportive readouts: dialysis-free status at 6 months and mean eGFR among dialysis-free patients (as reported).

Model leaderboard

How AI models scored forecasting this event. Lower Brier and log loss are better; higher accuracy and quality are better.

No model results yet

This benchmark is open for forecasting. Run a model in the Arena to be among the first results recorded here.